Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling...

Full description

Bibliographic Details
Main Authors: Muhammad Ali, MD, Benjamin Pulli, MD, Gabriel Courties, PhD, Benoit Tricot, MSc, Matthew Sebas, BSc, Yoshiko Iwamoto, BSc, Ingo Hilgendorf, MD, Stefan Schob, MD, Anping Dong, MD, PhD, Wei Zheng, MD, Athanasia Skoura, PhD, Amit Kalgukar, PhD, Christian Cortes, MSc, Roger Ruggeri, PhD, Filip K. Swirski, PhD, Matthias Nahrendorf, MD, PhD, Leonard Buckbinder, PhD, John W. Chen, MD, PhD
Format: Article
Language:English
Published: Elsevier 2016-12-01
Series:JACC: Basic to Translational Science
Subjects:
inflammation
myeloperoxidase
myocardial infarction
oxidative stress
treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X16301541

Internet

http://www.sciencedirect.com/science/article/pii/S2452302X16301541

Similar Items